# Hongcheng Investment

> Hongcheng Investment is a VC fund backing Biotechnology, Medical and Biopharma. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Jun 2026
- Lead investor: 33%
- Last updated: Aug 2026

Hongcheng Investment is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Biopharma | 2 | 33% |
| Health Care | 1 | 17% |
| Clean Energy | 1 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Angel | 1 | 17% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| WattDance | WattDance is an energy intelligence startup developing advanced physical AI large models for closed loop smart control. The company specializes in building unified networks that optimize source, grid, load, and storage environments. Its technology acts as an intelligent brain to maximize the efficiency of renewable energy assets and modern powergrids. |  | Angel | Jun 26, 2026 |  |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals. | $29.6M | Series C | Jun 02, 2026 |  |
| Best-Link Bioscience | Best-Link Bioscience is a high-tech enterprise engaged in innovative drug research and development, focusing on cutting-edge scientific discovery, advanced therapeutic technologies, and the creation of novel medicines to address unmet clinical needs and improve patient outcomes worldwide. | $36.7M | Series B | Dec 11, 2025 |  |
| Affinity | Affinity Biomedical Technology is a clinical biopharmaceutical company focusing on the development of global innovative anticancer drugs. | $55M | Series B | Dec 02, 2024 |  |
| Hengyu Biotechnology | Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | $27.8M | Series B | Mar 11, 2024 |  |
| Hicicare | Hicicare is a medical technology company that specializes in the development of pan-vascular interventional medical devices. | $14M | Series A | Dec 07, 2023 |  |

6 of 6 investments shown.

## Co-investors
- Hongyao Science and Technology — VC Fund, 3 deals together
- Anxin Guosheng Microchip Fund — VC Fund, 1 deal together
- [CAS Star](https://shizune.co/investors/profile/cas-star) — VC Fund, 1 deal together
- [China Growth Capital](https://shizune.co/investors/profile/china-growth-capital) — VC Fund, 1 deal together
- [China Reform Securities](https://shizune.co/investors/profile/china-reform-securities) — VC Fund, 1 deal together
- [Chiron Ventures](https://shizune.co/investors/profile/chiron-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Hongcheng Investment invest in?

Hongcheng Investment invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series B and Angel stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hongcheng Investment last invest?

The most recent investment recorded for Hongcheng Investment closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co